Clorox Reports Q1 Fiscal Year 2025 Results, Updates Outlook
Clorox (CLX) reported strong Q1 FY2025 results with net sales increasing 27% to $1.76 billion. Organic sales grew 31%, while gross margin improved 740 basis points to 45.8%. Diluted EPS rose 371% to $0.80, and adjusted EPS increased 280% to $1.86. The company completed the divestiture of its Better Health VMS business and updated its FY2025 outlook, raising gross margin expectations to 100-150 basis points improvement and adjusted EPS guidance to $6.65-$6.90. All segments except International showed significant growth, with double-digit organic sales increases across reportable segments.
Clorox (CLX) ha riportato risultati solidi per il primo trimestre dell'anno fiscale 2025, con vendite nette aumentate del 27% a $1,76 miliardi. Le vendite organiche sono cresciute del 31%, mentre il margine lordo è migliorato di 740 punti base, arrivando al 45,8%. EPS diluito è aumentato del 371% a $0,80, e l'EPS rettificato è cresciuto del 280% a $1,86. L'azienda ha completato la dismissione della sua attività Better Health VMS e ha aggiornato le previsioni per l'anno fiscale 2025, aumentando le aspettative sul margine lordo da un miglioramento di 100-150 punti base e guidando l'EPS rettificato a $6,65-$6,90. Tutti i segmenti, tranne quello internazionale, hanno mostrato una crescita significativa, con aumenti delle vendite organiche a doppia cifra in tutti i segmenti riportabili.
Clorox (CLX) reportó resultados sólidos para el primer trimestre del año fiscal 2025, con ventas netas que aumentaron un 27% a $1.76 mil millones. Las ventas orgánicas crecieron un 31%, mientras que el margen bruto mejoró 740 puntos básicos hasta el 45.8%. EPS diluido aumentó un 371% a $0.80, y el EPS ajustado creció un 280% a $1.86. La empresa completó la desinversión de su negocio Better Health VMS y actualizó su perspectiva para el año fiscal 2025, elevando las expectativas del margen bruto a una mejora de 100-150 puntos básicos y la guía de EPS ajustado a $6.65-$6.90. Todos los segmentos, excepto el internacional, mostraron un crecimiento significativo, con aumentos de ventas orgánicas de dos dígitos en todos los segmentos reportables.
Clorox (CLX)는 2025 회계연도 1분기에 대한 강력한 실적을 보고했으며, 순매출은 27% 증가하여 $17억 6천만 달러에 달했습니다. 유기적 매출은 31% 증가했으며, 총 이익률은 740 베이시스 포인트 개선되어 45.8%에 이르렀습니다. 희석 주당순이익은 371% 상승하여 $0.80에 달했고, 조정된 주당순이익은 280% 증가하여 $1.86이 되었습니다. 이 회사는 Better Health VMS 사업의 매각을 완료했으며, 2025 회계연도 전망을 업데이트하여 총 이익률 개선 기대치를 100-150 베이시스 포인트로 높이고 조정된 주당순이익 가이던스를 $6.65-$6.90으로 상향 조정했습니다. 국제 부문을 제외한 모든 부문에서 큰 성장을 보여주었으며, 보고 가능 부문에서 유기적 매출이 두 자릿수로 증가했습니다.
Clorox (CLX) a annoncé de solides résultats pour le premier trimestre de l'exercice 2025, avec des ventes nettes en hausse de 27 % à $1,76 milliard. Les ventes organiques ont augmenté de 31 %, tandis que la marge brute s'est améliorée de 740 points de base pour atteindre 45,8 %. EPS dilué a augmenté de 371 % à 0,80 $, et l'EPS ajusté a augmenté de 280 % à 1,86 $. L'entreprise a finalisé la cession de son activité Better Health VMS et a mis à jour ses prévisions pour l'exercice 2025, en augmentant les attentes concernant la marge brute à une amélioration de 100 à 150 points de base et les prévisions d'EPS ajusté à 6,65 $ - 6,90 $. Tous les segments, à l'exception de l'international, ont montré une croissance significative, avec des augmentations des ventes organiques à deux chiffres dans tous les segments rapportables.
Clorox (CLX) hat für das erste Quartal des Geschäftsjahres 2025 starke Ergebnisse gemeldet, mit einem Anstieg des Nettoumsatzes um 27 % auf $1,76 Milliarden. Der organische Umsatz wuchs um 31 %, während die Bruttomarge um 740 Basispunkte auf 45,8 % anstieg. Verdünntes EPS stieg um 371 % auf $0,80, und das bereinigte EPS erhöhte sich um 280 % auf $1,86. Das Unternehmen hat die Veräußertung seines Better Health VMS-Geschäfts abgeschlossen und seine Prognose für das Geschäftsjahr 2025 aktualisiert, indem die Erwartungen für die Bruttomarge auf eine Verbesserung um 100-150 Basispunkte erhöht und die Prognose für das bereinigte EPS auf $6,65-$6,90 angehoben wurde. Alle Segmente, mit Ausnahme des internationalen, zeigten ein signifikantes Wachstum, wobei in allen berichtbaren Segmenten zweistellige organische Umsatzsteigerungen verzeichnet wurden.
- Net sales increased 27% to $1.76 billion with organic sales up 31%
- Gross margin improved significantly by 740 basis points to 45.8%
- Adjusted EPS grew 280% to $1.86
- Operating cash flow increased 1,005% to $221 million
- Company raised its gross margin and EPS outlook for FY2025
- International segment sales decreased 4%
- $118 million after-tax charge from Better Health VMS business divestiture
- Expected net sales to be flat to down 2% for FY2025
Insights
A strong quarter for Clorox with impressive growth metrics. Net sales surged
The company's strategic divestiture of the Better Health VMS business, though resulting in a
The comprehensive recovery across all segments, particularly in Health and Wellness (
Strategic investments in innovation and advertising, while maintaining
First-Quarter Fiscal Year 2025 Summary
Following is a summary of key results for the first quarter, which reflect the lapping of the impacts of the August 2023 cyberattack and include the company's Better Health Vitamins, Minerals and Supplements (VMS) business through its sale date of Sept. 10, 2024. Results also reflect the prior divestiture of the
- Net sales increased
27% to compared to a$1.76 billion 20% net sales decrease in the year-ago quarter. The increase was driven largely by higher volume reflecting the lapping of the cyberattack. Organic sales1 were up31% . - Gross margin increased 740 basis points to
45.8% from38.4% in the year-ago quarter, primarily driven by higher volume and cost savings. - Diluted net earnings per share (diluted EPS) increased
371% to from$0.80 in the year-ago quarter. The increase is driven by strong operational performance and lapping of the cyberattack, partially offset by a$0.17 94 cent charge from the sale of the Better Health VMS business. - Adjusted EPS1 increased
280% to from$1.86 in the year-ago quarter, primarily due to higher net sales and cost savings, partially offset by increased advertising investments.$0.49 - Year-to-date net cash provided by operations was
compared to$221 million in the year-ago period, representing a 1,$20 million 005% increase.
"We achieved better-than-expected results this quarter and fully restored overall market share, enabling us to maintain our sales outlook and raise our gross margin and EPS outlook for the year," said Chair and CEO Linda Rendle. "As our consumers remain under pressure, we're focused on delivering superior value, strong innovation and continued investment in our brands to win with consumers and grow share. Anchored by the strength of our portfolio and the advancement of our IGNITE strategy, we are confident we are taking the right steps to deliver consistent and profitable growth for the long-term."
This press release includes certain non-GAAP financial measures. See "Non-GAAP Financial Information" at the end of this press release for more details.
Strategic and Operational Highlights
The following are recent highlights of business and environmental, social and governance achievements:
- Delivered double-digit organic sales growth1 across all reportable segments, grew shares in most of its categories, and fully restored overall market share.
- Continued to invest behind value superiority with strong advertising, merchandising and platform-expanding innovations including Clorox Scentiva Bleach Lavender & Jasmine, plant-based Clorox EcoClean Disinfecting Wipes and more durable Glad ForceFlex MaxStrength trash bags.
- Achieved the eighth consecutive quarter of gross margin expansion, supported by another strong quarter of cost savings, and is on track to fully rebuild gross margin in fiscal year 2025.
- Completed the Better Health VMS divestiture, following on the prior sale of the
Argentina business, to continue evolving the portfolio in support of the company's goal to reduce volatility and accelerate sales growth, as well as structurally improve its margin. - Named a Safer Choice Partner of the Year by the
U.S. Environmental Protection Agency for the seventh time, recognized as one of the World's Best Companies by Time, named one of the World's Most Trustworthy Companies by Newsweek and listed as one of America's Best Employers for Women by Forbes.
Key Segment Results
The following is a summary of key first-quarter results by reportable segment. In addition to strong operational performance, first-quarter results reflect the lapping of the impacts of the August 2023 cyberattack. All comparisons are with the first quarter of fiscal year 2024 unless otherwise stated.
Health and Wellness (Cleaning; Professional Products)
- Net sales increased
38% , driven by 38 points of higher volume and 2 points of favorable mix, offset by 2 points of higher trade promotion spending. - Segment adjusted EBIT2 increased
126% , primarily behind higher net sales and cost savings, partially offset by increased advertising investments.
Household (Bags and Wraps; Cat Litter; Grilling)
- Net sales increased
38% , with 43 points of higher volume partially offset by 5 points driven by unfavorable mix and higher trade promotion spending. - Segment adjusted EBIT increased 1,
600% , primarily due to higher net sales and cost savings, partially offset by higher advertising investments.
Lifestyle (Food; Water Filtration; Natural Personal Care)
- Net sales increased
40% , with 48 points of higher volume partially offset by 8 points driven by unfavorable mix and higher trade promotion spending. - Segment adjusted EBIT increased
247% , due to higher net sales, partially offset by higher advertising investments.
International (Sales Outside the
- Net sales decreased
4% , mainly driven by the impact of theArgentina divestiture and 2 points of unfavorable foreign exchange rates. ExcludingArgentina and effects of foreign exchange rate changes, organic sales1 grew11% , driven by 11 points of organic volume growth. - Segment adjusted EBIT increased
3% , due to higher volume growth excludingArgentina , partially offset by higher advertising investments.
Divestiture of Better Health Vitamins, Minerals and Supplements Business
As previously disclosed on Sep. 10, 2024, the company completed the divestiture of its Better Health VMS business in its entirety. The divested business includes the Natural Vitality, NeoCell, Rainbow Light and RenewLife brands, relevant trademarks and licenses, and associated manufacturing and distribution facilities in
Fiscal Year 2025 Outlook
The company is updating the following elements of its fiscal year 2025 outlook:
- Gross margin is now expected to be up about 100 to 150 basis points, primarily due to the benefits of holistic margin management efforts, partially offset by cost inflation and higher trade promotion spending. This compares to the previous expectation of about 100 basis points.
- Fiscal year diluted EPS is now expected to be between
and$5.17 versus previously$5.42 and$4.95 , a year over year increase of$5.20 130% to141% , respectively, reflecting the lapping of several one-time charges recorded in the year-ago period. - Adjusted EPS is now expected to be between
and$6.65 compared to the previous estimate of$6.90 and$6.55 , a year over year increase of$6.80 8% to12% , respectively. Adjusted EPS excludes about of expense from long-term strategic investments in digital capabilities and productivity enhancements, a$0.60 charge in the first quarter from the loss on sale related to the divestiture of the Better Health VMS business, and a$0.94 benefit from cyberattack insurance recovery in the first quarter.$0.06
The company is confirming the following elements of its fiscal year 2025 outlook:
- The company continues to expect net sales to be flat to down
2% . Organic sales are still expected to be up3% to up5% , excluding about 2 points of negative impact from the divestiture of the company's business inArgentina and about 3 points of negative impact from the divestiture of the Better Health VMS business. - Selling and administrative expenses continue to be expected to be between
15% to16% of net sales, which includes about 150 basis points of impact from the company's strategic investments in digital capabilities and productivity enhancements. - Advertising and sales promotion spending is still expected to be about
11% to11.5% of net sales, reflecting the company's ongoing commitment to invest behind its brands. - The company's effective tax rate is still expected to be about
28% . Excluding the impact of the Better Health VMS sale, the company expects its fiscal year adjusted effective tax rate to be about24% .
1 Organic sales growth / (decrease) and adjusted EPS are non-GAAP measures. See Non-GAAP Financial Information at the end of this press release for reconciliations to the most comparable GAAP measures. | |||
2 Adjusted EBIT is a non-GAAP measure. See Non-GAAP Financial Information at the end of this press release for reconciliations to the most comparable GAAP measures. |
Clorox Earnings Conference Call Schedule
At approximately 4:15 p.m. ET today, Clorox will post prepared management remarks regarding its first quarter fiscal year 2025 results.
At 5 p.m. ET today, the company will host a live Q&A audio webcast with Chair and CEO Linda Rendle and Chief Financial Officer Kevin Jacobsen to discuss the results.
Links to the live (and archived) webcast, press release and prepared remarks can be found at Clorox Quarterly Results.
For More Detailed Financial Information
Visit the company's Quarterly Results for the following:
- Supplemental unaudited volume and sales growth information
- Supplemental unaudited gross margin drivers information
- Supplemental unaudited cash flow information and free cash flow reconciliation
- Supplemental unaudited reconciliation of earnings (losses) before interest and taxes (EBIT) and adjusted EBIT
- Supplemental unaudited reconciliation of adjusted earnings per share (EPS) and adjusted effective tax rate (ETR)
Note: Percentage and basis-point, or point, changes noted in this press release are calculated based on rounded numbers, except for per-share data and the effective tax rate.
About The Clorox Company
The Clorox Company (NYSE: CLX) champions people to be well and thrive every single day. Its trusted brands include Brita®, Burt's Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®, Liquid-Plumr® and Pine-Sol® as well as international brands such as Clorinda®, Chux® and Poett®. Headquartered in
CLX-F
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements regarding the expected or potential impact of the company's operational disruption stemming from a cyberattack, and any such forward-looking statements involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management's estimates, beliefs, assumptions and projections. Words such as "could," "may," "expects," "anticipates," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," "will," "predicts," and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management's expectations, are described in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024, as updated from time to time in the company's Securities and Exchange Commission filings. These factors include, but are not limited to: unfavorable general economic and geopolitical conditions beyond our control, including supply chain disruptions, labor shortages, wage pressures, rising inflation, the interest rate environment, fuel and energy costs, foreign currency exchange rate fluctuations, weather events or natural disasters, disease outbreaks or pandemics, such as COVID-19, terrorism, and unstable geopolitical conditions, including ongoing conflicts in the
The company's forward-looking statements in this press release are based on management's current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this press release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.
Non-GAAP Financial Information
- This press release contains non-GAAP financial information related to organic sales growth / (decrease), adjusted EPS, adjusted effective tax rate ("adjusted ETR") and segment adjusted EBIT for the first quarter of fiscal year 2025, as well as adjusted EPS outlook and adjusted ETR outlook for fiscal year 2025. The reasons management believes these measures are useful to investors are described below. Certain non-GAAP financial measures may be considered in determining incentive compensation.
- Clorox defines organic sales growth / (decrease) as GAAP net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions or divestitures.
- Organic sales growth/(decrease) outlook for fiscal year 2025 excludes about 2 points of negative impact from the divestiture of the company's business in
Argentina and about 3 points of negative impact from the divestiture of the Better Health VMS business. - Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the company was operating and expects to continue to operate throughout the relevant periods, and the company's estimate of the impact of foreign exchange rate changes, which are difficult to predict and out of the control of the company and management. However, organic sales growth / (decrease) may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.
- Adjusted EPS is defined as diluted earnings per share that excludes or has otherwise been adjusted for significant items that are nonrecurring or unusual. The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
- Adjusted ETR is defined as the effective tax rate that excludes or that has otherwise been adjusted for significant items that are nonrecurring or unusual.
- Adjusted EPS and adjusted ETR are supplemental information that management uses to help evaluate the company's historical and prospective financial performance on a consistent basis over time. Management believes that by adjusting for certain items affecting comparability of performance over time, such as the pension settlement charge, incremental costs, net of insurance recoveries, related to the August 2023 cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items, investors and management are able to gain additional insight into the company's underlying operating performance on a consistent basis over time. However, adjusted EPS and adjusted ETR may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.
- Adjusted EBIT represents earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs, net of insurance recoveries, related to the August 2023 cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability during the period. The company uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance, and allocate resources to each segment. Management believes that the presentation of adjusted EBIT excluding these items is useful to investors to assess operating performance on a consistent basis by removing the impact of the items that management believes do not directly reflect the performance of each segment's underlying operations. However, adjusted EBIT may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments.
- The reconciliation tables below refer to the equivalent GAAP measures adjusted as applicable for the following items:
Divestiture of Better Health Vitamins, Minerals and Supplements Business
As previously disclosed on Sep. 10, 2024, the company completed the divestiture of its Better Health VMS business in its entirety. The divested business includes the Natural Vitality, NeoCell, Rainbow Light and RenewLife brands, relevant trademarks and licenses, and associated manufacturing and distribution facilities in
Due to the nature, scope and magnitude of this charge, the company's management believes presenting this charge as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.
Cyberattack Costs
As previously disclosed, incremental costs were incurred by the company as the result of the August 2023 cyberattack. These costs related primarily to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs from the resulting disruption to the company's business operations. Costs associated with ongoing cybersecurity monitoring and prevention as well as enhancement to the company's cybersecurity program are not included within this adjustment.
In the first quarter of fiscal year 2025, the company received
Due to the nature, scope and magnitude of these costs, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.
Digital Capabilities and Productivity Enhancements Investment
As announced in August 2021, the company plans to invest in transformative technologies and processes over a five-year period. This investment began in fiscal year 2022, and includes replacement of the company's enterprise resource planning system and transitioning to a cloud-based platform as well as the implementation of a suite of other digital technologies. The total incremental transformational investment is expected to be
Of the total investment, approximately
Due to the nature, scope and magnitude of this investment, these costs are considered by management to represent incremental transformational costs above the historical normal level of spending for information technology to support operations. Since these strategic investments, including incremental operating costs, will cease at the end of the investment period, are not expected to recur in the foreseeable future and are not considered representative of the company's underlying operating performance, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period-over-period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.
The following table provides reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease), the most comparable GAAP measure:
Three months ended Sep. 30, 2024 | |||||||||
Percentage change versus the year-ago period | |||||||||
Health and | Household | Lifestyle | International | Total | |||||
Net sales growth / (decrease) (GAAP) | 38 % | 38 % | 40 % | (4) % | 27 % | ||||
Add: Foreign exchange | — | — | — | 2 | — | ||||
Add/(Subtract): Divestitures/acquisitions (2) | — | — | — | 13 | 4 | ||||
Organic sales growth / (decrease) (non-GAAP) | 38 % | 38 % | 40 % | 11 % | 31 % |
(1) | Total Company includes Corporate and Other. Corporate and Other includes the results of the Better Health VMS business through the date of divestiture. |
(2) | The divestiture impact is calculated as net sales from the |
The following tables provide reconciliations of adjusted diluted earnings per share (non-GAAP) to diluted earnings per share, the most comparable GAAP measure, and adjusted effective tax rate (non-GAAP) to effective tax rate, the most comparable GAAP measure:
Adjusted Diluted Earnings Per Share (EPS) and Adjusted Effective Tax Rate (ETR) | ||||||||||||
(Dollars in millions except per share data) | ||||||||||||
Diluted earnings per share | Effective tax rate | |||||||||||
Three months ended | Three months ended | |||||||||||
9/30/2024 | 9/30/2023 | % Change | 9/30/2024 | 9/30/2023 | ||||||||
As reported (GAAP) | $ 0.80 | $ 0.17 | 371 % | 41.8 % | 14.6 % | |||||||
Loss on divestiture (1) | 0.94 | — | (16.8) % | — | ||||||||
Cyberattack costs, net of insurance | (0.06) | 0.15 | 0.1 % | 2.8 % | ||||||||
Streamlined operating model (7) | — | — | — % | — | ||||||||
Digital capabilities and productivity | 0.18 | 0.17 | (0.1) % | 3.2 % | ||||||||
As adjusted (non-GAAP) | $ 1.86 | $ 0.49 | 280 % | 25.0 % | 20.6 % |
(1) | During the three months ended Sep. 30, 2024, the company incurred an after tax charge of | |||||||||||
(2) | During the three months ended Sep. 30, 2024, the company recognized approximately | |||||||||||
(3) | During the three months ended Sep. 30, 2024 and 2023, the company incurred approximately | |||||||||||
Three months ended | |||||
9/30/2024 | 9/30/2023 | ||||
External consulting fees (a) | $ 20 | $ 21 | |||
IT project personnel costs (b) | 2 | 2 | |||
Other (c) | 7 | 4 | |||
Total | $ 29 | $ 27 |
(a) | Comprised of third-party consulting fees incurred to assist in the project management and end-to-end systems integration of this transformative investment. The company relies on consultants for certain capabilities required for these programs that the company does not maintain internally. These costs support the implementation of these programs incremental to the company's normal IT costs and will not be incurred following implementation. | ||||||||||
(b) | Comprised of labor costs associated with internal IT project management teams that are utilized to oversee the new system implementations. Given the magnitude and transformative nature of the implementations planned, the necessary project management costs are incremental to the historical levels of spend and will no longer be incurred subsequent to implementation. As a result of this long-term strategic investment, the company considers these costs not reflective of the ongoing costs to operate its business. | ||||||||||
(c) | Comprised of various other expenses associated with the company's new system implementations, including company personnel dedicated to the project that have been backfilled with either permanent or temporary resources in positions that are considered part of normal operating expenses. | ||||||||||
Full year 2025 outlook (estimated range) | ||||||||||
Diluted earnings per share | Effective Tax Rate | |||||||||
Low | High | Midpoint | ||||||||
As estimated (GAAP) | $ 5.17 | $ 5.42 | 28 % | |||||||
Loss on divestiture | 0.94 | 0.94 | (4) % | |||||||
Cyberattack costs, net of insurance | (0.06) | (0.06) | — | |||||||
Digital capabilities and productivity | 0.60 | 0.60 | — | |||||||
As adjusted (non-GAAP) | $ 6.65 | $ 6.90 | 24 % |
(4) | In fiscal year 2025, the company expects to incur approximately |
The following table provides reconciliation of adjusted EBIT (non-GAAP) to earnings before income taxes, the most comparable GAAP measure:
Reconciliation of earnings | |||
Three months ended | |||
9/30/2024 | 9/30/2023 | ||
Earnings before income taxes | $ 177 | $ 29 | |
Interest income | (3) | (10) | |
Interest expense | 21 | 21 | |
Loss on divestiture | 118 | — | |
Cyberattack costs, net of insurance recoveries | (10) | 24 | |
Digital capabilities and productivity enhancements investment | 29 | 27 | |
Adjusted EBIT | $ 332 | $ 91 |
Condensed Consolidated Statements of Earnings (Unaudited) | |||||
Dollars in millions, except per share data | |||||
Three months ended | |||||
09/30/2024 | 09/30/2023 | ||||
Net sales | $ 1,762 | $ 1,386 | |||
Cost of products sold | 955 | 854 | |||
Gross profit | 807 | 532 | |||
Selling and administrative expenses | 281 | 276 | |||
Advertising costs | 201 | 165 | |||
Research and development costs | 31 | 29 | |||
Loss on divestiture | 118 | — | |||
Interest expense | 21 | 21 | |||
Other (income) expense, net | (22) | 12 | |||
Earnings before income taxes | 177 | 29 | |||
Income tax expense | 74 | 4 | |||
Net earnings | 103 | 25 | |||
Less: Net earnings attributable to noncontrolling interests | 4 | 3 | |||
Net earnings attributable to Clorox | $ 99 | $ 22 | |||
Net earnings per share attributable to Clorox | |||||
Basic net earnings per share | $ 0.80 | $ 0.17 | |||
Diluted net earnings per share | $ 0.80 | $ 0.17 | |||
Weighted average shares outstanding (in thousands) | |||||
Basic | 123,795 | 123,973 | |||
Diluted | 124,677 | 124,650 |
Reportable Segment Information | |||||
(Unaudited) | |||||
Dollars in millions | |||||
Net sales | |||||
Three months ended | |||||
9/30/2024 | 9/30/2023 | % Change(1) | |||
Health and Wellness | $ 698 | $ 504 | 38 % | ||
Household | 447 | 325 | 38 | ||
Lifestyle | 320 | 229 | 40 | ||
International | 259 | 270 | (4) | ||
Reportable segment total | 1,724 | 1,328 | |||
Corporate and Other (2) | 38 | 58 | (34) | ||
Total | $ 1,762 | $ 1,386 | 27 % | ||
Segment adjusted EBIT | |||||
Three months ended | |||||
9/30/2024 | 9/30/2023 | % Change(1) | |||
Health and Wellness | $ 235 | $ 104 | 126 % | ||
Household | 60 | (4) | 1,600 | ||
Lifestyle | 66 | 19 | 247 | ||
International | 35 | 34 | 3 | ||
Reportable segment total | 396 | 153 | |||
Corporate and Other (2) | (64) | (62) | (3) | ||
Total | $ 332 | $ 91 | 265 % | ||
Interest income | 3 | 10 | |||
Interest expense | (21) | (21) | |||
Loss on divestiture (3) | (118) | — | |||
Cyberattack costs, net of insurance recoveries (4) | 10 | (24) | |||
Digital capabilities and productivity enhancements investment (5) | (29) | (27) | |||
Earnings before income taxes | $ 177 | $ 29 | 510 % |
(1) | Percentages based on rounded numbers. | |||||
(2) | Corporate and Other includes the Better Health VMS business. | |||||
(3) | Represents the loss on divestiture of the Better Health VMS business of | |||||
(4) | Represents cyberattack insurance recoveries of | |||||
(5) | Represents expenses related to the company's digital capabilities and productivity enhancements investment of |
Condensed Consolidated Balance Sheets | |||||||||||
Dollars in millions | |||||||||||
9/30/2024 | 6/30/2024 | 9/30/2023 | |||||||||
(Unaudited) | (Unaudited) | ||||||||||
ASSETS | |||||||||||
Current assets | |||||||||||
Cash and cash equivalents | $ | 278 | $ | 202 | $ | 518 | |||||
Receivables, net | 595 | 695 | 581 | ||||||||
Inventories, net | 594 | 637 | 710 | ||||||||
Prepaid expenses and other current assets | 109 | 88 | 102 | ||||||||
Total current assets | 1,576 | 1,622 | 1,911 | ||||||||
Property, plant and equipment, net | 1,242 | 1,315 | 1,317 | ||||||||
Operating lease right-of-use assets | 341 | 360 | 328 | ||||||||
Goodwill | 1,233 | 1,228 | 1,246 | ||||||||
Trademarks, net | 503 | 538 | 541 | ||||||||
Other intangible assets, net | 78 | 143 | 162 | ||||||||
Other assets | 524 | 545 | 486 | ||||||||
Total assets | $ | 5,497 | $ | 5,751 | $ | 5,991 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||
Current liabilities | |||||||||||
Notes and loans payable | $ | 4 | $ | 4 | $ | 347 | |||||
Current operating lease liabilities | 83 | 84 | 88 | ||||||||
Accounts payable and accrued liabilities | 1,472 | 1,486 | 1,678 | ||||||||
Income Taxes Payable | 20 | — | 115 | ||||||||
Total current liabilities | 1,579 | 1,574 | 2,228 | ||||||||
Long-term debt | 2,482 | 2,481 | 2,478 | ||||||||
Long-term operating lease liabilities | 315 | 334 | 290 | ||||||||
Other liabilities | 874 | 848 | 837 | ||||||||
Deferred income taxes | 23 | 22 | 27 | ||||||||
Total liabilities | 5,273 | 5,259 | 5,860 | ||||||||
Commitments and contingencies | |||||||||||
Stockholders' equity | |||||||||||
Preferred stock | — | — | — | ||||||||
Common stock | 131 | 131 | 131 | ||||||||
Additional paid-in capital | 1,297 | 1,288 | 1,246 | ||||||||
Retained earnings | 31 | 250 | 299 | ||||||||
Treasury stock | (1,252) | (1,186) | (1,219) | ||||||||
Accumulated other comprehensive net (loss) income | (147) | (155) | (494) | ||||||||
Total Clorox stockholders' equity (deficit) | 60 | 328 | (37) | ||||||||
Noncontrolling interests | 164 | 164 | 168 | ||||||||
Total stockholders' equity | 224 | 492 | 131 | ||||||||
Total liabilities and stockholders' equity | $ | 5,497 | $ | 5,751 | $ | 5,991 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/clorox-reports-q1-fiscal-year-2025-results-updates-outlook-302291742.html
SOURCE The Clorox Company
FAQ
What was Clorox (CLX) Q1 2025 revenue?
What is Clorox (CLX) adjusted EPS guidance for fiscal 2025?
How much did Clorox (CLX) gross margin improve in Q1 2025?